Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors

Neonatology

Volumn 104, Issue 1, 2013, Pages 65-70

  Leibovitch, Leah ^a   Rymer Haskel, Noa ^a   Schushan Eisen, Irit ^a   Kuint, Jacob ^a   Strauss, Tzipora ^a   Maayan Metzger, Ayala ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Clinical signs; Neonatal outcome; Serotonin reuptake inhibitors

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

APGAR SCORE; ARTICLE; CONTROLLED STUDY; CONVULSION; DISEASE COURSE; EXCHANGE BLOOD TRANSFUSION; FEEDING DISORDER; FEMALE; HEAD CIRCUMFERENCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MALROTATION SYNDROME; NERVOUSNESS; NEWBORN; ONSET AGE; OUTCOME ASSESSMENT; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESTLESSNESS; RETROSPECTIVE STUDY; TRANSIENT TACHYPNEA OF THE NEWBORN; AMNION FLUID; CYANOSIS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEEDING DIFFICULTY; FEVER; GASTROINTESTINAL SYMPTOM; INFANT; LIFE THREAT; LOW DRUG DOSE; MECONIUM; PATIENT MONITORING; PERINATAL PERIOD; PRENATAL DRUG EXPOSURE; SIDE EFFECT;

APGAR SCORE; EATING DISORDERS; FEMALE; HUMANS; INFANT BEHAVIOR; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, SMALL FOR GESTATIONAL AGE; LARYNGOPHARYNGEAL REFLUX; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PSYCHOMOTOR AGITATION; RESPIRATORY DISTRESS SYNDROME, NEWBORN; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 84878093221     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000350506     Document Type: Article

References (17)

1. Kallen B: Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-316.
2. Koren G, Nordeng H: Antidepressant use during pregnancy: the benefit-risk ratio. Am J Obstet Gynecol 2012; 207: 157-163.
3. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-610.
4. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-1015.
5. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63: 898-906.
6. Lund N, Pedersen LH, Henriksen TB: Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163: 949-954.
7. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G: Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006; 160: 173-176.
8. Zeskind PS, Stephens LE: Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113: 368-375.
9. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005; 293: 2372-2383.
10. Jordan AE, Jackson GL, Deardorff D, Shivakumar G, McIntire DD, Dashe JS: Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. J Matern Fetal Neonatal Med 2008; 21: 745-751.
11. Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF, Fletcher AP, Schou JS: Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163-169.
12. Sie SD, Wennink JM, van Driel JJ, te Winkel AG, Boer K, Casteelen G, van Weissenbruch MM: Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation. Arch Dis Child Fetal Neonatal Ed 2012; 97:F472-F476.
13. Reefhuis J, Rasmussen SA, Friedman JM: Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 2188-2190, author reply 2188-2190.
14. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-Connor E, Orwoll E, Bliziotes MM; for the Osteoporotic Fractures in Men Study Group: Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167: 1246-1251.
15. Dubnov-Raz G, Hemila H, Vurembrand Y, Kuint J, Maayan-Metzger A: Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density. Early Hum Dev 2012; 88: 191-194.
16. Pawluski JL, Brain UM, Underhill CM, Hammond GL, Oberlander TF: Prenatal SSRI exposure alters neonatal corticosteroid binding globulin, infant cortisol levels, and emerging HPA function. Psychoneuroendocrinology 2012; 37: 1019-1028.
17. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-587.